At the American Association for Cancer Research (AACR) special conference on acute myeloid leukemia and myelodysplastic syndrome, taking place January 23-25, 2023 in Austin, TX, BriSTAR Immunotech will be unveiling its cutting-edge T-cell receptor (TCR) and antigen receptor (STAR)-T cell therapy technology platform. This clinical-stage cell therapy company is on the forefront of the fight against cancer, and its innovative approach is sure to make a huge impact on the medical world.
Dr. James Pan, CEO of BriSTAR Immunotech, is excited to share that their LILRB4 STAR-T cell therapy has shown impressive anti-tumor activity against AML in preclinical models. This remarkable feat reinforces the promise of the STAR-T technology platform to revolutionize the treatment of cancer.
About LILRB4 STAR-T
BriSTAR Immunotech has revolutionized the treatment of relapsed/refractory acute myeloid leukemia (R/R AML) with their innovative LILRB4 STAR-T cell therapy. This powerful new therapy utilizes the state-of-the-art STAR-T platform to introduce two novel nano-antibodies fused to the alpha and beta chains of the STAR structure, allowing for superior antigen engagement and increased cytotoxicity against this aggressive form of cancer. In December 2022, the program received the coveted Orphan Drug Designation from the U.S. FDA, providing a beacon of hope for those suffering from R/R AML.
About Acute Myeloid Leukemia (AML)
AML is a devastating blood cancer that affects both adults and children, with over 20 000 cases reported in the United States alone every year. China is one of the countries with the highest incidence of AML, reporting 13,200 cases and 7,100 deaths annually. Unfortunately, there are limited treatments available for those with relapse/refractory AML, and their survival period is only 5-9 months. It is for this reason that AML remains a complex and challenging disease to treat.
About STAR-T Platform
BriSTAR Immunotech’s groundbreaking STAR-T cell therapy technology platform is revolutionizing the fight against cancer. This cutting-edge platform features natural T cell characteristics, such as sensitive target engagement and strong tumor infiltration, enabling the development of dual-targeting T cell products for both hematological and solid tumors. With its innovative approach, STAR-T is paving the way to a brighter future for cancer patients.
The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted an investigational new drug (IND) application for the CD19/CD20 STAR-T cell injection (HXYT-001) for the treatment of recurrent/refractory non-Hodgkin lymphoma (B-NHL). Moreover, exploratory clinical studies involving STAR-T cells have been initiated to explore their potential for the treatment of various types of solid tumors.
About BriSTAR Immunotech
BriSTAR Immunotech Ltd is revolutionizing the fight against cancer and viral infections with its innovative cell therapy solutions. Founded in 2018, the company has two proprietary technology platforms, STAR-T and enTCR-T, that utilize full TCR-signaling complexes to engage and kill cancer cells and co-stimulatory signaling to tackle viral infections. BriSTAR’s current pipeline includes product candidates for AML and solid tumors, as well as viral infections, with its leading product, a dual targeting CD19/CD20 STAR-T candidate, already in clinical trials to treat relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).